ELUTIA INC. - CLASS A COMMON STOCK

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

05 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Participate in Upcoming Investor Conferences

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Announces Second Quarter 2024 Results

07 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

31 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

30 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

11 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Announces $13.26 Million Registered Direct Offering

17 Jun 2024 07:01:00 By Nasdaq GlobeNewswire

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

17 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Regains Compliance with Nasdaq Listing Requirements

10 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

13 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

06 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

20 Sep 2023 07:30:00 By Nasdaq GlobeNewswire